Amyloid-beta (monoclonal antibody)

Assets acting on this target.

Class
Anti-amyloid-beta monoclonal antibody

Amyloid-beta is a small peptide generated by sequential cleavage of a larger transmembrane protein. In some individuals it misfolds and self-associates, progressing from soluble oligomers to protofibrils and finally to the insoluble fibrils that accumulate as extracellular plaques in the brain. This aggregation process is central to the amyloid cascade hypothesis of Alzheimer's disease, which proposes that accumulating amyloid-beta species trigger downstream neuronal injury, inflammation, and eventual cognitive decline. Monoclonal antibodies directed against amyloid-beta are designed to bind specific forms of the peptide (monomers, soluble oligomers, protofibrils, or the fibrillar material within plaques) and to promote their clearance, largely through recruitment of the brain's resident immune cells. Because different antibodies preferentially recognize different conformations, their intended biological effects (soluble species neutralization versus plaque removal) can vary. Active vaccines pursue a related goal by different means: rather than supplying a ready-made antibody, they stimulate a person's own immune system to generate antibodies against amyloid-beta. Across modalities, the shared rationale is that reducing the burden of aggregated amyloid-beta in the brain may slow the neurodegenerative process, making this mechanism a central strategy investigated across the spectrum of Alzheimer's disease and related amyloid-associated conditions.

By indication

Related mechanisms

Amyloid-beta (monoclonal antibody) drugs compared

9 drugs, stage by indication
9 drugs acting on Amyloid-beta (monoclonal antibody): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
DonanemabKisunlaEli Lillymonoclonal antibodyApprovedApproved in Alzheimer's Disease
LecanemabLeqembiBiogen, Eisaimonoclonal antibodyApprovedApproved in Alzheimer's Disease
RemternetugEli Lillymonoclonal antibodyPhase 3Phase 3 in Alzheimer's Disease
TrontinemabRochebispecific antibodyPhase 3Phase 3 in Alzheimer's Disease
SHR-1707Jiangsu Hengrui Pharmaceuticalsmonoclonal antibodyPhase 2Phase 2 in Alzheimer's Disease
ABBV-1758AbbViemonoclonal antibody (transferrin-receptor shuttle)Phase 1/2Phase 1/2 in Alzheimer's Disease
ALIA-1758AbbViemonoclonal antibody (BBB-crossing)Phase 1Phase 1 in Alzheimer's Disease
CM383Keymed Biosciencesmonoclonal antibodyPhase 1Phase 1 in Alzheimer's Disease
PMN310ProMIS Neurosciences, Inc.monoclonal antibodyPhase 1Phase 1 in Alzheimer's Disease; Phase 1 in Early Alzheimer's Disease

← all mechanisms